Albireo Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 130

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 6

  • Investments
  • 1

Albireo General Information

Description

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Contact Information

Website
www.albireopharma.com
Formerly Known As
Biodel
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 53 State Street
  • 19th Floor
  • Boston, MA 02109
  • United States
+1 (857)
Primary Industry
Biotechnology
Acquirer
Ipsen (Pharmaceuticals)
Vertical(s)
Life Sciences
Former Stock Listing
ALBO
Corporate Office
  • 53 State Street
  • 19th Floor
  • Boston, MA 02109
  • United States
+1 (857)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Albireo Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Albireo‘s full profile, request access.

Request a free trial

Albireo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization
Biotechnology
Boston, MA
130 As of 2021

Florham Park, NJ
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Albireo Competitors (19)

One of Albireo’s 19 competitors is Phathom Pharmaceuticals, a Formerly VC-backed company based in Florham Park, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Phathom Pharmaceuticals Formerly VC-backed Florham Park, NJ
Aldeyra Therapeutics Formerly VC-backed Lexington, MA
Voyager Therapeutics Corporation Lexington, MA
Minerva Neurosciences Formerly VC-backed Burlington, MA
ACADIA Pharmaceuticals Formerly VC-backed San Diego, CA
You’re viewing 5 of 19 competitors. Get the full list »

Albireo Patents

  • 409

    Total Documents Applications and Grants

  • Total Patents Families

  • 232

    Granted

  • 51

    Pending

  • Expiring in next 12 mo

Albireo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023390975-A1 Asbt inhibitors in the treatment of renal diseases Pending 09-Dec-2022
US-20240207286-A1 Asbt inhibitors in the treatment of renal diseases Pending 09-Dec-2022
AU-2023390972-A1 Cocrystals of odevixibat Pending 09-Dec-2022
AU-2023374724-A1 Treating alagille syndrome (algs) Pending 03-Nov-2022
US-20240173333-A1 Treating alagille syndrome (algs) Pending 03-Nov-2022 A61K31/554
To view Albireo’s complete patent history, request access »

Albireo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Albireo Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Albireo‘s full profile, request access.

Request a free trial

Albireo Acquisitions (1)

Albireo’s most recent deal was a Merger/Acquisition with Biodel for . The deal was made on 03-Nov-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Biodel 03-Nov-2016 Merger/Acquisition Pharmaceuticals
To view Albireo’s complete acquisitions history, request access »

Albireo FAQs

  • When was Albireo founded?

    Albireo was founded in 2008.

  • Where is Albireo headquartered?

    Albireo is headquartered in Boston, MA.

  • What is the size of Albireo?

    Albireo has 130 total employees.

  • What industry is Albireo in?

    Albireo’s primary industry is Biotechnology.

  • Is Albireo a private or public company?

    Albireo is a Private company.

  • What is the current valuation of Albireo?

    The current valuation of Albireo is .

  • What is Albireo’s current revenue?

    The current revenue for Albireo is .

  • How much funding has Albireo raised over time?

    Albireo has raised $102M.

  • Who are Albireo’s investors?

    Aberdeen Asset Management, Biodel, Decheng Capital, HBM Healthcare Investments, and Kreos Capital are 5 of 11 investors who have invested in Albireo.

  • Who are Albireo’s competitors?

    Phathom Pharmaceuticals, Aldeyra Therapeutics, Voyager Therapeutics, Minerva Neurosciences, and ACADIA Pharmaceuticals are some of the 19 competitors of Albireo.

  • When was Albireo acquired?

    Albireo was acquired on 02-Mar-2023.

  • Who acquired Albireo?

    Albireo was acquired by Ipsen (Pharmaceuticals).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »